Imeglimin

ApprovedSmall molecule

Imeglimin is a small molecule that works as a Mitochondrial Bioenergetics Modulator.[2] It is being used across 2 indications, with its most advanced program in Approved.[1]

Imeglimin is one of 63 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesApproved

Type 2 Diabetes MellitusApproved

Active, not recruiting

Type 2 DiabetesApproved

Approved

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Imeglimin

PPoxel SA

Approved

2 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Type 2 Diabetes Mellitus

NCT05366868

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy

Not yet recruiting·MMansoura University·Phase 4·NCT07436182·176 enrolled

A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed·PPoxel SA·Phase 2·NCT01951235·315 enrolled

Tics1 trial

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

Completed·PPoxel SA·Phase 1·NCT03802786·14 enrolled

Type 2 Diabetes Mellitus1 trial

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Recruiting·NNational Center for Global Health and Medicine, Japan·Phase 4·NCT05366868·567 enrolled

ALS1 trial

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Completed·PPoxel SA·Phase 1·NCT02924337·55 enrolled

Unspecified3 trials

Effect of Cimetidine on the PK of Imeglimin

Completed·PPoxel SA·Phase 1·NCT03618316·16 enrolled

Bioequivalence of Imeglimin Tablet Formulations

Completed·PPoxel SA·Phase 1·NCT03646331·16 enrolled

Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

Completed·PPoxel SA·Phase 1·NCT02373150·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Imeglimin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Imeglimin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Imeglimin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Poxel SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Mitochondrial Bioenergetics Modulator[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPoxel SA

Imeglimin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Type 2 Diabetes2 trials

Tics1 trial

Type 2 Diabetes Mellitus1 trial

ALS1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News